Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
5 hedge funds and large institutions have $1.17M invested in Yield10 Bioscience, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
23% less capital invested
Capital invested by funds: $1.53M → $1.17M (-$358K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
+$98.3K |
| 2 |
Renaissance Technologies
New York
|
+$59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.62K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.81K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$1K |
| 5 |
WEC
Winslow Evans & Crocker
Boston,
Massachusetts
|
-$15 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Birchview Capital
Burlington,
Vermont
| $722K | – | – | – |
|
|
CC
2
Cannell & Co
New York
| $223K | – | – | – |
|
|
GC
3
GMT Capital
Atlanta,
Georgia
| $107K | +$98.3K | +35 | New |
|
|
4
Renaissance Technologies
New York
| $65K | +$59K | +21 | New |
|
5
BlackRock
New York
| $49K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $1K | -$5.62K | -2 | Closed |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2.81K | -1 | Closed |
|
|
8
Group One Trading
Chicago,
Illinois
| – | -$1K | – | – |
|
|
9
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$1K | – | – |
|
|
WEC
10
Winslow Evans & Crocker
Boston,
Massachusetts
| – | -$15 | – | – |
|
YTEN Hedge Fund Activity: Q3 2017 in Review
5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q3 2017, worth a combined $1.17M — down 23% from $1.53M a quarter earlier.
Fund positioning in YTEN was balanced in Q3 2017: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was GMT Capital, opening a new position worth an estimated $98.3K. The largest seller was UBS Group, exiting entirely with an estimated $5.62K sold.
- 5 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $1.17M of Yield10 Bioscience, Inc. Common Stock stock for Q3 2017, down 23% quarter-over-quarter.
- 2 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q3 2017 and 2 closed out, a net change of 0 holders.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q3 2017 was GMT Capital, an estimated $98.3K added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q3 2017 was UBS Group, an estimated $5.62K sold.
Based on aggregated 13F filings for Q3 2017.